Trials in Sickle Cell Disease

Pediatric Neurology

Volumn 34, Issue 6, 2006, Pages 450-458

  Kirkham, Fenella J ^a   Lerner, Norma B ^b   Noetzel, Michael ^c   DeBaun, Michael R ^c   Datta, Avijit K ^d   Rees, David C ^e   Adams, Robert J ^f  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF ROCHESTER   (United States)

^c WASHINGTON UNIVERSITY   (United States)

^d UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; IBUPROFEN; OPIATE;

ARTICLE; BLOOD TRANSFUSION; BRAIN INFARCTION; CLINICAL TRIAL; COGNITION; COMA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HEALTH CARE POLICY; HUMAN; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PILOT STUDY; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PULSE OXIMETRY; RISK FACTOR; SEIZURE; SICKLE CELL ANEMIA; STROKE; TIME; TREATMENT DURATION; VELOCITY;

ADOLESCENT; ANEMIA, SICKLE CELL; ASPIRIN; BLOOD TRANSFUSION; CEREBROVASCULAR ACCIDENT; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; CONTINUOUS POSITIVE AIRWAY PRESSURE; FIBRINOLYTIC AGENTS; HUMANS;

EID: 33744799139     PISSN: 08878994     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pediatrneurol.2005.10.017     Document Type: Article

References (57)

1. Earley C.J., Kittner S.J., Feeser B.R., et al. Stroke in children and sickle-cell disease. Neurology 51 (1998) 169-176
2. Ohene-Frempong K., Weiner S.J., Sleeper L.A., et al. Cerebrovascular accidents in sickle cell disease. Rates and risk factors. Blood 91 (1998) 288-294
3. Kirkham F.J., Hewes D.K.M., Hargrave D., Wade A., Lane R., and Evans J. Nocturnal hypoxaemia predicts CNS events in sickle cell disease. Lancet 357 (2001) 1656-1659
4. Stockman J.A., Nigro M.A., Mishkin M.M., and Oski F.A. Occlusion of the large cerebral vessels in sickle cell anemia. N Engl J Med 287 (1972) 846-849
5. Wiznitzer M., Ruggieri P.M., Masaryk T.J., Ross J.S., Modic M.T., and Berman B. Diagnosis of cerebrovascular disease in sickle cell anemia by magnetic resonance angiography. J Pediatr 117 (1990) 551-555
6. van Mierlo T.D., van den Berg H.M., Nievelstein R.A.J., and Braun K.P.J. An unconscious girl with sickle cell disease. Lancet 361 (2003) 136
7. Sébire G., Tabarki B., Saunders D.E., et al. Cerebral venous sinus thrombosis in children. Risk factors, presentation, diagnosis and outcome. Brain 128 (2005) 477-489
8. Henderson J.N., Noetzel M.J., McKinstry R.C., White D.A., Armstrong M., and DeBaun M.R. Reversible posterior leukencephalopathy syndrome and silent cerebral infarcts are associated with acute chest syndrome in sickle cell disease. Blood 101 (2003) 415-419
9. Lee K.H., McKie V.C., Sekul E.A., Adams R.J., and Nichols F.T. Unusual encephalopathy after acute chest syndrome. Acute necrotizing encephalitis. J Pediatr Hematol/Oncol 24 (2002) 585-588
10. Pegelow C.H., Macklin E.A., Moser F.G., et al. Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease. Blood 99 (2002) 3014-3018
11. Bernaudin F., Verlhac S., Freard F., et al. Multicenter prospective study of children with sickle cell disease. Radiographic and psychometric correlation. J Child Neurol 15 (2000) 333-343
12. Saunders D.E., Bynevelt M., Hewes D.K.M., et al. MRI in children with sickle cell disease without overt stroke. Dev Med Child Neurol 43 Suppl.90 (2001) 27 (abstr.)
13. Armstrong F.D., Thompson R.J., Wang W., et al. Cognitive functioning and brain magnetic resonance imaging in children with sickle cell disease. Pediatrics 97 (1996) 864-870
14. DeBaun M.R., Schatz J., Siegel M.J., et al. Cognitive screening examinations for silent cerebral infarcts in sickle cell disease. Neurology 50 (1998) 1678-1682
15. Watkins K.E., Hewes D.K.M., Connelly A., et al. Cognitive deficits associated with frontal lobe infarction in children with sickle cell disease. Dev Med Child Neurol 40 (1998) 536-543
16. Wang W., Enos L., Gallagher D., et al. Cooperative Study of Sickle Cell Disease. Neuropsychologic performance in school-aged children with sickle cell disease: A report from the Cooperative Study of Sickle Cell Disease. J Pediatr 139 (2001) 391-397
17. Scothorn D.J., Price C., Schwartz D., et al. Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. J Pediatr 140 (2002) 348-354
18. Dobson S.R., Holden K.R., Nietert P.J., et al. Moyamoya syndrome in childhood sickle cell disease. A predictive factor for recurrent cerebrovascular events. Blood 99 (2002) 3144-3150
19. Powars D., Wilson B., Imbus C., Pegelow C., and Allen J. The natural history of stroke in sickle cell disease. Am J Med 65 (1978) 461-471
20. Wood D.H. Cerebrovascular complications of sickle cell anemia. Stroke 9 (1978) 73-75
21. Wilimas J., Goff J.R., Anderson Jr. H.R., Langston J.W., and Thompson E. Efficacy of transfusion therapy for one to two years in patients with sickle cell disease and cerebrovascular accidents. J Pediatr 96 (1980) 205-208
22. Moohr J.W., Wilson H., and Pang E.J. Strokes and their management in sickle cell disease. In: Fried W. (Ed). Comparative clinical aspects of sickle cell disease (1982), Elsevier, North Holland, Amsterdam 101-111
23. Russell M.O., Goldberg H.I., Hodson A., et al. Effect of transfusion therapy on arteriographic abnormalities and on recurrence of stroke in sickle cell disease. Blood 63 (1984) 162-169
24. Wang W.C., Kovnar E.H., Tonkin I.L., et al. High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease. J Pediatr 118 (1991) 377-382
25. Cohen A.R., Martin M.B., Silber J.H., Kim H.C., Ohene-Frempong K., and Schwartz E. A modified transfusion program for prevention of stroke in sickle cell disease. Blood 79 (1992) 1657-1661
26. Rana S., Houston P.E., Surana N., Shalaby-Rana E.I., and Castro O.L. Discontinuation of long-term transfusion therapy in patients with sickle cell disease and stroke. J Pediatr 131 (1997) 757-760
27. Pegelow C.H., Adams R.J., McKie V., et al. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr 126 (1995) 896-899
28. Prengler M., Ganesan V., Dick M., et al. Risk factors for recurrent transient ischaemic event and stroke in sickle cell disease. Dev Med Child Neurol 43 Suppl. 90 (2001) 27 (abstr.)
29. Ware R.E., Zimmerman S.A., Sylvestre P.B., et al. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. J Pediatr 145 (2004) 346-352
30. Wang W.C., Wynn L.W., Rogers Z.R., Scott J.P., Lane P.A., and Ware R.E. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. J Pediatr 139 (2001) 790-796
31. Adams R.J., McKie V.C., Carl E.M., et al. Long-term stroke risk in children with sickle cell disease screened with transcranial Doppler. Ann Neurol 42 (1997) 699-704
32. Miller S.T., Macklin E.A., Pegelow C.H., et al. Cooperative Study of Sickle Cell Disease. Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: A report from the Cooperative Study of Sickle Cell Disease. J Pediatr 139 (2001) 385-390
33. Adams R.J., and STOP investigators. Prevention of stroke by transfusion in sickle cell disease. N Engl J Med 339 (1998) 5-11
34. Goldstein L.B., Adams R., Becker K., et al. Primary prevention of ischemic stroke. A statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 32 (2001) 280-299
35. Fullerton H.J., Adams R.J., Zhao S., and Johnston S.C. Declining stroke rates in Californian children with sickle cell disease. Blood 104 (2004) 336-339
36. Adams R.J., and Brambilla D. Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med 353 (2005) 2769-2778
37. Pegelow C.H., Macklin E.A., Moser F.G., et al. Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease. Blood 99 (2002) 3014-3018
38. Armstrong F.D., Thompson Jr. R.J., Wang W., et al. Cognitive functioning and brain magnetic resonance imaging in children with sickle cell disease. Neuropsychology Committee of the Cooperative Study of Sickle Cell Disease. Pediatrics 97 (1996) 864-870
39. Watkins K.E., Hewes D.K., Connelly A., et al. Cognitive deficits associated with frontal-lobe infarction in children with sickle cell disease. Dev Med Child Neurol 40 (1998) 536-543
40. Schatz J., White D.A., Moinuddin A., Armstrong M., and DeBaun M.R. Lesion burden and cognitive morbidity in children with sickle cell disease. J Child Neurol 17 (2002) 891-895
41. Koshy M., Thomas C., and Goodwin J. Vascular lesions in the central nervous system in sickle cell disease (neuropathology). J Assoc Acad Minor Phys 1 (1990) 71-78
42. Pegelow C.H., Wang W., Granger S., et al. STOP Trial. Silent infarcts in children with sickle cell anemia and abnormal cerebral artery velocity. Arch Neurol 58 (2001) 2017-2021
43. Greenberg J., Ohene-Frempong K., Halus J., Way C., and Schwartz E. Trial of low doses of aspirin as prophylaxis in sickle cell disease. J Pediatr 102 (1983) 781-784
44. Zago M.A., Costa F.F., Ismael S.J., Tone L.G., and Bottura C. Treatment of sickle cell diseases with aspirin. Acta Haematol 72 (1984) 61-64
45. Chen Z.M., Sandercock P., Pan H.C., et al., CAST and IST collaborative groups. Indications for early aspirin use in acute ischemic stroke. A combined analysis of 40,000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. Stroke 31 (2000) 1240-1249
46. Gorelick P.B., Richardson D., Kelly M., et al. African American Antiplatelet Stroke Prevention Study Investigators. Aspirin and ticlopidine for prevention of recurrent stroke in black patients. A randomized trial. JAMA 289 (2003) 2947-2957
47. Ridker P.M., Cook N.R., Lee I.M., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352 (2005) 1293-1304
48. Inwald D.P., Kirkham F.J., Peters M.J., et al. Platelet and leucocyte activation in childhood sickle cell disease. Association with nocturnal hypoxaemia. Br J Haem 111 (2000) 474-481
49. Osamo N.O., Photiades D.P., and Famodu A.A. Therapeutic effect of aspirin in sickle cell anaemia. Acta Haematol 66 (1981) 102-107
50. Hargrave D.R., Wade A., Evans J.P.M., Hewes D.K.M., and Kirkham F.J. Nocturnal hypoxemia and painful sickle cell crises in children. Blood 101 (2003) 846-848
51. Bass J.L., Corwin M., Gozal D., et al. The effect of chronic or intermittent hypoxia on cognition in childhood. A review of the evidence. Pediatrics 114 (2004) 805-816
52. Steen R.G., Xiong X., Mulhern R.K., Langston J.W., and Wang W.C. Subtle brain abnormalities in children with sickle cell disease. Relationship to blood hematocrit. Ann Neurol 45 (1999) 279-286
53. Ali N.J., Pitson D., and Stradling J.R. Sleep disordered breathing. Effect of adenotonsillectomy on behaviour and psychological functioning. Eur J Pediatr 155 (1992) 56-62
54. Chervin R.D., Dillon J.E., Bassetti C., Ganoczy D.A., and Pituch K.J. Symptoms of sleep disorders, inattention, and hyperactivity in children. Sleep 20 (1997) 1185-1192
55. Goodman R. The Strengths and Difficulties Questionnaire. A research note. J Child Psychol Psychiatry 38 (1997) 581-586
56. Reinhard E.H., Moore C.V., Dubach R., and Wade L.J. Depressant effects of high concentrations of inspired oxygen on erythrocytogenesis. Observations on patients with sickle cell anemia with a description of the observed toxic manifestations of oxygen. J Clin Invest 2 (1944) 682-698
57. Embury S.H., Garcia J.F., Mohandas N., Pennathur-Das R., and Clark M.R. Effects of oxygen inhalation on endogenous erythropoietin kinetics, erythropoiesis, and properties of blood cells in sickle-cell anemia. N Engl J Med 311 (1984) 291-295